Norvancomycin monohydrochloride
Based on 1 publication(s) in Google Scholar
Norvancomycin hydrochloride is a cell wall synthesis inhibitor targeting peptidoglycan precursors of Gram-positive bacteria and cannot pass the blood-brain barrier. Norvancomycin hydrochloride can competitively bind to peptidoglycan precursors, irreversibly inhibit bacterial cell wall synthesis, and exert antibacterial activity. Norvancomycin hydrochloride is mainly used in the study of Gram-positive bacterial infections, especially infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE). Norvancomycin hydrochloride can also be incorporated into the bionic calcium phosphate coating of titanium implants to enhance antibacterial activity and inhibit postoperative orthopedic infections.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 95.25%
- CAS 番号: 213997-73-0
- 分子式: C65H74Cl3N9O24
- 分子量:1471.69
-
保管条件:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
FDA-Approved Drug Library
HY-L022
-
Drug Repurposing Compound Library
HY-L035
-
Antibacterial Compound Library
HY-L049
-
Anti-COVID-19 Compound Library
HY-L052
-
NMPA-Approved Drug Library
HY-L053
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Off-patent Drug Library
HY-L141
-
Anti-Drug-Resistant Compound Library
HY-L169
-
Bioactive Compound Library Max
HY-L181
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
MedChemExpress（MCE）の使用を引用している文献 Norvancomycin monohydrochloride
More
生物活性
|
Glycopeptide |
Norvancomycin hydrochloride (100-1000 mg/L; 48 h) can be coated with biomimetic calcium phosphate coating. The effective content increases first and then stabilizes with the increase of solution concentration. Norvancomycin hydrochloride reaches 2.16 μg/mg coating at 600 mg/L, and the release is fast first and then slow[1].
In the in vitro antibacterial experiment, the inhibition zone of Norvancomycin hydrochloride (100-800 mg/L; 24 h) against Staphylococcus aureus increases with the increase of concentration, significantly inhibiting bacterial adhesion[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
The pharmacokinetics of Norvancomycin (100 mg/kg; intravenous injection; single dose; single) in male Kunming mice shows that its elimination half-life is 42.43 minutes and the clearance rate is 0.0233 mL·kg-1·min-1[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
化学情報
-
CAS 番号 213997-73-0
-
性状 Solid
-
分子量 1471.69
-
分子式 C65H74Cl3N9O24
-
Color White to off-white
-
SMILES
O[C@@H]1[C@@H](O[C@@](O[C@@H](C)[C@H]2O)([H])C[C@@]2(N)C)[C@@H](O[C@H](CO)[C@H]1O)OC3=C(OC4=CC=C([C@H]([C@H]5NC([C@H](N)CC(C)C)=O)O)C=C4Cl)C=C([C@](NC([C@@H](NC5=O)CC(N)=O)=O)([H])C(N[C@](C6=O)([H])C7=CC8=C(O)C=C7)=O)C=C3OC9=CC=C([C@H]([C@](C(N[C@@](C(O)=O)([H])C%10=C8C(O)=CC(O)=C%10)=O)([H])N6)O)C=C9Cl.Cl
-
別名
N-Demethylvancomycin monohydrochloride; NVCM monohydrochloride
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
J Control Release
cRGD enables rapid phagocytosis of liposomal vancomycin for intracellular bacterial clearance. [Abstract]2022 Apr:344:202-213. PMID: 35235809
溶剤 & 溶解度
H2O : ≥ 100 mg/mL (67.95 mM)
DMSO : ≥ 100 mg/mL (67.95 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (1.70 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (1.70 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 100 mg/mL (67.95 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
純度とドキュメンテーション
-
データシート (286 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Zhou T, et al. Study on pharmacokinetics and tissue distribution of norvancomycin in rats by CE with electrochemical detection. Electrophoresis. 2006 May;27(9):1790-6. [Content Brief]
[2]. Pan CJ, et al. Enhancing the antibacterial activity of biomimetic HA coatings by incorporation of norvancomycin. J Orthop Sci. 2011 Jan;16(1):105-13. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 0.6795 mL | 3.3975 mL | 6.7949 mL | 16.9873 mL |
| 5 mM | 0.1359 mL | 0.6795 mL | 1.3590 mL | 3.3975 mL | |
| 10 mM | 0.0679 mL | 0.3397 mL | 0.6795 mL | 1.6987 mL | |
| 15 mM | 0.0453 mL | 0.2265 mL | 0.4530 mL | 1.1325 mL | |
| 20 mM | 0.0340 mL | 0.1699 mL | 0.3397 mL | 0.8494 mL | |
| 25 mM | 0.0272 mL | 0.1359 mL | 0.2718 mL | 0.6795 mL | |
| 30 mM | 0.0226 mL | 0.1132 mL | 0.2265 mL | 0.5662 mL | |
| 40 mM | 0.0170 mL | 0.0849 mL | 0.1699 mL | 0.4247 mL | |
| 50 mM | 0.0136 mL | 0.0679 mL | 0.1359 mL | 0.3397 mL | |
| 60 mM | 0.0113 mL | 0.0566 mL | 0.1132 mL | 0.2831 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Norvancomycin monohydrochloride 関連分類
HY-B1924 関連分類
Powered by Bioz